Detalles de la búsqueda
1.
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.
Clin Infect Dis
; 78(4): 995-1004, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38092042
2.
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Clin Infect Dis
; 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38663013
3.
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Clin Infect Dis
; 77(4): 593-605, 2023 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052343
4.
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.
AIDS
; 38(4): 497-508, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079588
5.
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Lancet HIV
; 11(5): e321-e332, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621392
6.
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV.
AIDS
; 37(3): 467-475, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001525
7.
Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37509301
Resultados
1 -
7
de 7
1
Próxima >
>>